Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jennifer Divine

MOHS-Micrographic Surgery Fort Collins, CO Medical Doctor

NPI 1063779072 CMS profile 1390240

1260 Doctor's Lane, Fort Collins, CO 80524

Open in the dashboard

General payments

$3,722

184 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer Divine of Fort Collins, CO is reported in the CMS Open Payments database as having received $3,722 across 184 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $299 16
2024 General $1,005 39
2023 General $561 25
2022 General $808 38
2021 General $507 24
2020 General $311 26
2019 General $232 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Divine
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Jennifer Divine were reported at $299. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Jennifer Divine MOHS-Micrographic Surgery median Middle half National median
2019 $232 $316 $106–$785 $163
2020 $311 $162 $68–$412 $114
2021 $507 $243 $87–$654 $132
2022 $808 $300 $102–$887 $149
2023 $561 $364 $125–$1,010 $160
2024 $1,005 $445 $142–$1,108 $164
2025 $299 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,118 51 payments
  2. Sun Pharmaceutical Industries Inc. $348 16 payments
  3. Pfizer Inc. $236 10 payments
  4. LEO Pharma Inc. $209 22 payments
  5. Genzyme Corporation $203 10 payments
  6. Galderma Laboratories, L.P. $189 11 payments
  7. UCB, Inc. $174 8 payments
  8. Kerecis Limited $138 2 payments
  9. Amgen Inc. $119 6 payments
  10. Regeneron Healthcare Solutions, Inc. $113 2 payments
  11. Other $876 46 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,494 180 payments
  2. Education $228 4 payments
Products named General payments · program years 2019–2025
  1. SKYRIZI $718 30 payments
  2. RINVOQ $313 16 payments
  3. DUPIXENT $273 13 payments
  4. ILUMYA $235 14 payments
  5. CIBINQO $217 9 payments
  6. ENSTILAR $175 20 payments
  7. HUMIRA $141 7 payments
  8. Kerecis Omega3 SurgiClose $138 2 payments
  9. Kerecis Omega3 Marigen Wound Care $138 2 payments
  10. Kerecis Omega3 Marigen Wound Care $138 2 payments
  11. Other $2,304 104 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

614

Median for Dermatology: 534

Drug cost

$130,446

Median for Dermatology: $67,151

Branded share of claims

7.5%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 27 $110,382
Clobetasol Propionate Generic 86 $5,214
Tacrolimus Generic 12 $2,343
Doxycycline Monohydrate Generic 46 $1,883
Pimecrolimus Generic 11 $1,551
Tretinoin Generic 11 $1,191
Triamcinolone Acetonide Generic 66 $1,029
Fluorouracil Generic 12 $1,025
Ketoconazole Generic 43 $909
Clindamycin Phosphate Generic 22 $737

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$216,538

Of which drugs: $33

Medicare patients

674

Average age 72

Services billed

3,868

416 women, 258 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 52%
Arthritis 43%
Depression 21%
Ischemic heart disease 16%
Osteoporosis 16%
Diabetes 14%
Chronic kidney disease 14%
Atrial fibrillation 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 16 44 $33

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ILUMYA
  • Sun Pharmaceutical Industries Inc. $99
$99 — —
Bimzelx
  • UCB, Inc. $96
$96 — —
RINVOQ
  • AbbVie, Inc. $85
$85 — —
CIBINQO
  • PFIZER INC. $62
$62 — —
SKYRIZI
  • AbbVie, Inc. $62
$62 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

184 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record